Last reviewed · How we verify

NCT05309304

Cefazolin PK Study 3g vs 2g

Completed Phase 1 Last updated 12 October 2022
What this trial tests

Phase 1 trial testing Cefazolin in Healthy in 24 participants. Completed in 30 August 2022.

Timeline
14 February 2022
Primary endpoint
30 August 2022
30 August 2022

Quick facts

Lead sponsorBaxter Healthcare Corporation
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment24
Start date14 February 2022
Primary completion30 August 2022
Estimated completion30 August 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Baxter Healthcare Corporation — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study is to characterize the safety and tolerability of cefazolin after a single IV administration in healthy subjects in a 3 g/150 mL presentation to meet the increasing clinical need for the indication of perioperative prophylaxis in this patient population weighing greater than or equal to (≥) 120 kg.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Cefazolin

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Baxter Healthcare Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05309304.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing